GCM
IMVT icon

Graham Capital Management’s Immunovant IMVT Stock Holding History

Graham Capital Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-15,119
Closed -$244K – 1398
2025
Q3 		$244K Buy
+15,119
New +$245K ﹤0.01% 961
2022
Q2 		– Sell
-23,655
Closed -$130K – 1126
2022
Q1 		$130K Sell
23,655
-755
-3% -$4.7K ﹤0.01% 853
2021
Q4 		$207K Buy
+24,410
New +$202K 0.01% 456

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Graham Capital Management's IMVT Position: Q4 2025 in Review

Graham Capital Management sold out of Immunovant (IMVT) in Q4 2025, closing a stake of 15,119 shares — an estimated $244K sold.

Graham Capital Management first reported a position in IMVT in Q4 2021 and held it in 3 quarters. The position peaked at $244K in Q3 2025. 196 funds tracked by Wall St. Rank hold IMVT as of Q4 2025.

  • Graham Capital Management reported no remaining Immunovant position as of Q4 2025 after selling out during the quarter.
  • Graham Capital Management sold 15,119 Immunovant shares in Q4 2025, an estimated $244K.
  • Graham Capital Management first reported a position in Immunovant in Q4 2021 and held it in 3 quarters.
  • Graham Capital Management's Immunovant position peaked at $244K in Q3 2025.
  • 196 funds tracked by Wall St. Rank held Immunovant as of Q4 2025.

Based on Graham Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.